Editas Medicine, Inc.EDITNASDAQ
Loading
Revenue Growth Recovery in ProgressRecovering
Percentile Rank58
5Y CAGR-40.5%
Studio
Year-over-Year Change

Year-over-year revenue growth rate

5Y CAGR
-40.5%/yr
Long-term compound
Percentile
P58
Within normal range
vs 5Y Ago
0.1x
Contraction
Streak
1 yr
Consecutive growthRecovering
PeriodValue
202525.39%
2024-58.64%
2023296.32%
2022-22.83%
2021-71.85%
2020341.93%
2019-35.71%
2018132.64%
2017126.80%
2016271.58%